£2.5m deal extends GSK university link
A partnership between the University of Strathclyde and healthcare company GlaxoSmithKline has been backed with £2.5 million of new funding.
It takes the financial commitment to the collaboration to more than £7 million since it was set up in 2009 to help resarch into drug discovery and therapeutic treatments.
The partnership has helped 120 research students to date, with nearly 50 research papers published, 16 patents filed and eight students named inventors.
The partnership extension will see 42 PhD studentships created, 24 of which will be fully-funded industrial PhD studentships based at GSK, with secondments to Strathclyde.
Strathclyde programme director, Professor Billy Kerr, said: “The key principle behind the programme continues to be the sharing of knowledge, expertise, and experience between the two organisations.
“Collaboration with industry is at the heart of how we operate at Strathclyde.”
Dr Harry Kelly, director of chemistry operations and GSK programme director, said: “This further extension to our collaborations with Strathclyde is driven by the mutual research benefits and career development opportunities for our talented graduate staff and other researchers associated with GSK.”
Professor Sir Jim McDonald, principal of the University of Strathclyde, said: “At Strathclyde, working side-by-side with business, industry and government is in the University’s DNA – and is central to our mission as a leading international technological university.”